Anne Puel Selected Research

Job Syndrome (Hyper-IgE Syndrome)

1/2021	Case Report: Interleukin-2 Receptor Common Gamma Chain Defect Presented as a Hyper-IgE Syndrome.
1/2020	Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome.
1/2019	The nature of human IL-6.
11/2018	Somatic alterations compromised molecular diagnosis of DOCK8 hyper-IgE syndrome caused by a novel intronic splice site mutation.
1/2018	Human hyper-IgE syndrome: singular or plural?
12/2016	Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity.
9/2015	Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome.
9/2012	Immunity to infection in IL-17-deficient mice and humans.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne Puel Research Topics

Disease

20	Infections 01/2022 - 02/2004
17	Chronic Mucocutaneous Candidiasis 11/2021 - 02/2010
11	COVID-19 01/2022 - 10/2020
11	Candidiasis (Moniliasis) 01/2022 - 08/2013
11	Ectodermal Dysplasia (Aplasia Cutis Congenita) 01/2017 - 10/2003
8	Pneumonia (Pneumonitis) 01/2022 - 07/2012
8	Job Syndrome (Hyper-IgE Syndrome) 01/2021 - 09/2012
7	Mycoses (Diseases, Fungus) 01/2020 - 12/2012
7	Virus Diseases (Viral Diseases) 09/2015 - 06/2007
6	Autoimmune Diseases (Autoimmune Disease) 10/2021 - 11/2008
6	Inflammation (Inflammations) 01/2021 - 11/2005
5	Encephalitis (Encephalitis, Rasmussen) 01/2021 - 12/2004
5	autosomal recessive Candidiasis familial chronic mucocutaneous 01/2020 - 12/2012
5	Bacterial Infections (Bacterial Infection) 12/2010 - 10/2003
4	Chronic Granulomatous Disease 01/2022 - 03/2011
4	Communicable Diseases (Infectious Diseases) 01/2022 - 02/2008
4	IRAK4 Deficiency 01/2021 - 12/2006
4	Atopic Dermatitis (Atopic Eczema) 01/2021 - 09/2015
4	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2019 - 08/2011
4	hypohidrotic Ectodermal dysplasia with immune deficiency 07/2011 - 10/2003
3	Invasive Fungal Infections 01/2020 - 10/2013
3	Abscess 01/2017 - 01/2008
3	Trichophyton infection 07/2015 - 12/2013
3	Herpes Simplex Encephalitis (Herpes Encephalitis) 09/2011 - 12/2008
3	Pneumococcal Infections 11/2010 - 12/2003
3	Sepsis (Septicemia) 11/2009 - 05/2005
2	type 1 Autoimmune polyendocrinopathy syndrome 09/2021 - 12/2016
2	Eosinophilia 01/2021 - 07/2012
2	Invasive Candidiasis 01/2021 - 12/2013
2	Reinfection 01/2021 - 01/2018
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/2020 - 09/2015
2	Aspergillosis 01/2020 - 12/2013
2	Onychomycosis (Tinea Unguium) 11/2019 - 01/2019
2	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 01/2017 - 10/2015
2	Autosomal Recessive 3 Severe Congenital Neutropenia 12/2013 - 01/2005
2	Lymphopenia (Lymphocytopenia) 07/2012 - 12/2006
2	Herpes Simplex 09/2011 - 09/2010
2	Fever (Fevers) 08/2011 - 01/2008
2	Meningitis 11/2009 - 05/2005
2	Incontinentia Pigmenti (Bloch Sulzberger Syndrome) 04/2006 - 12/2004
1	Pulmonary Alveolar Proteinosis 01/2022
1	X-Linked Combined Immunodeficiency Diseases (X Linked Severe Combined Immunodeficiency) 01/2021
1	Dyskinesias (Dyskinesia) 01/2021
1	Asymptomatic Infections 01/2021
1	Yellow Fever 01/2021

Drug/Important Bio-Agent (IBA)

22	Interleukin-17 (Interleukin 17)IBA 11/2021 - 02/2010
14	AutoantibodiesIBA 01/2022 - 01/2008
14	CytokinesIBA 01/2022 - 10/2007
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2004
12	NF-kappa B (NF-kB)IBA 02/2008 - 10/2003
8	InterferonsIBA 09/2021 - 09/2010
5	Antiviral Agents (Antivirals)IBA 01/2021 - 12/2007
5	Immunoglobulin G (IgG)IBA 01/2021 - 01/2008
5	Immunoglobulin E (IgE)IBA 01/2018 - 07/2012
5	STAT1 Transcription FactorIBA 07/2017 - 01/2005
5	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2017 - 12/2003
4	InterleukinsIBA 01/2021 - 09/2013
4	Biological ProductsIBA 01/2019 - 01/2008
4	Interleukin-23 (Interleukin 23)IBA 12/2018 - 02/2008
4	NF-KappaB Inhibitor alphaIBA 07/2006 - 10/2003
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2008
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2022 - 01/2018
3	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2021 - 03/2011
3	AntibodiesIBA 01/2021 - 11/2008
3	Interferon Type IIBA 10/2020 - 06/2007
3	Toll-Like Receptor 3IBA 10/2020 - 09/2010
3	Interleukin-12 (IL 12)IBA 12/2018 - 02/2008
3	LigandsIBA 01/2018 - 10/2003
3	Interferon LambdaIBA 12/2008 - 06/2007
3	I-kappa B KinaseIBA 07/2006 - 10/2003
2	VaccinesIBA 01/2022 - 01/2016
2	AcidsIBA 01/2021 - 01/2017
2	Interleukin-15 (Interleukin 15)IBA 01/2021 - 12/2006
2	interleukin-21 (interleukin 21)IBA 01/2021 - 10/2015
2	Transforming Growth Factor-beta Type II ReceptorIBA 11/2019 - 07/2008
2	Phosphotransferases (Kinase)IBA 12/2014 - 09/2011
2	Complement System Proteins (Complement)IBA 07/2014 - 12/2003
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 10/2013 - 09/2010
2	Interleukin-22 (IL-22)IBA 09/2012 - 02/2010
2	TNF Receptor-Associated Factor 3IBA 09/2011 - 09/2010
2	C-Reactive ProteinIBA 08/2011 - 01/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2010 - 10/2003
2	Toll-Like Receptors (Toll-Like Receptor)IBA 09/2007 - 12/2006
1	dihydrorhodamine 123IBA 01/2022
1	AntigensIBA 10/2021
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 01/2021
1	Protein Kinase CIBA 01/2021
1	Interleukin-13IBA 01/2021
1	Cytokine Receptors (Cytokine Receptor)IBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	Interleukin-9 (Interleukin 9)IBA 01/2021
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2021
1	Interleukin-7 (Interleukin 7)IBA 01/2021
1	Interleukin-5 (Interleukin 5)IBA 01/2021
1	Interleukin-4 (Interleukin 4)IBA 01/2021
1	Prednisolone (Predate)FDA LinkGeneric 01/2021

Therapy/Procedure

4	Therapeutics 01/2019 - 12/2004
2	Hematopoietic Stem Cell Transplantation 01/2017 - 07/2006
2	Transplantation 01/2017 - 07/2006
2	Antibiotic Prophylaxis 07/2012 - 11/2010